Revista Internacional de Inflamación, Cáncer y Terapia Integrativa

Abstracto

Profiles of Endoglinand Vascular Endothelial Growth Factor-Based on Staging and Histological Grading of Colorectal Cancer, and Its Relationship with Bevacizumab Therapy Cancer

Rahmawati Minhajat

ABSTRACT: This study evaluated the profile of CD105 (Endoglin) and VEGF protein based on staging

and histopathological grading of Colorectal Cancer, and evaluated its relationship with

bevacizumab therapy. A total of 88 cases of colorectal adenocarcinoma were included in this study.

The levels of VEGF and CD105 were evaluated with ELISA. There was a significant difference in

CD105 protein level (p=0.002) between metastases and non-metastases subjects, where CD105

level is higher in metastatic colorectal adenocarcinoma (4.59ng/ml). There was no significant

difference of VEGF protein level based on the presence of metastasis (p=0.625); however, VEGF

levels tended to be higher in subjects with metastases (650.27pg/ml). There was a significant

difference of CD105 (p=0.038) and VEGF level (p=0.010) between the subjects who received

chemotherapy and those did not. The CD105 level was found higher in the subjects who received

chemotherapy (4.43ng/ml); otherwise VEGF level was found lower in subjects who received

chemotherapy (543.65pg/ml). There were a significant difference of CD105 level (p=0.003) and

VEGF levels (p=0.002) between subjects who received bevacizumab therapy and subjects who did

The levels of CD105 protein were higher in subjects who received bevacizumab therapy

(5.11ng/ml), in contrast, VEGF level was higher in subjects who did not receive bevacizumab

(645.92pg/ml). There was a significant positive correlation between CD105 and VEGF in subjects

who did not receive bevacizumab (p<0.01); in contrast, there was no significant correlation between

CD105 and VEGF levels in subjects who received bevacizumab (p>0.05). The results of this study

support a hypothesis of "escape mechanism" in the failure of anti-angiogenesis therapy (anti

VEGF).